• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Expanded ARCHER II Trial And New Credit Facility Might Change The Case For Investing In Annexon (ANNX)

    Simply Wall St·08/21/2026 22:28:41
    Listen to the news
    • Annexon recently reported a second-quarter 2026 net loss of US$55.35 million and advanced its late-stage pipeline, including expanding the Phase 3 ARCHER II trial for vonaprument in geographic atrophy with a dual Month 15 and Month 24 primary endpoint and launching an open-label extension study.
    • The company’s progress includes vonaprument’s Fast Track and PRIME designations, a planned Biologics License Application for tanruprubart in Guillain-Barré syndrome, and a US$200 million credit facility that together reshape how investors assess its clinical and regulatory trajectory.
    • With these developments and the enhanced ARCHER II design, we’ll consider how Annexon’s evolving late-stage pipeline influences its investment narrative.

    Find 49 companies with promising cash flow potential yet trading below their fair value.

    What Is Annexon's Investment Narrative?

    To own Annexon, you have to believe its complement platform can convert late‑stage assets into real commercial products before the cash burns too deep. The latest update on vonaprument, with ARCHER II’s dual Month 15 and Month 24 primary endpoints and an open‑label extension, sharpens the near‑term catalyst around Q4 2026 data and extends the clinical visibility out to 2027. At the same time, the $55.35 million quarterly net loss and reliance on a US$200 million credit facility keep financing and dilution risk firmly in focus, despite the interest‑only runway. Tanruprubart’s planned BLA filing for Guillain‑Barré syndrome and ongoing EMA review remain the other key inflection points, but the expanded ARCHER II design slightly raises trial complexity and timeline risk, even as it strengthens the potential regulatory package.

    However, one specific source of downside risk here is easy to underestimate. Despite retreating, Annexon's shares might still be trading above their fair value and there could be some more downside. Discover how much.

    Exploring Other Perspectives

    ANNX 1-Year Stock Price Chart
    ANNX 1-Year Stock Price Chart
    Three Simply Wall St Community fair values for Annexon span roughly US$9 to a very large US$90 per share, underlining how differently individual investors view the story. Against that wide spread, the sharpened focus on ARCHER II’s binary clinical readouts and ongoing cash burn gives you a clear set of upcoming events that could swing sentiment and performance sharply in either direction, so it pays to weigh several viewpoints before deciding where you stand.

    Explore 3 other fair value estimates on Annexon - why the stock might be a potential multi-bagger!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For Alternative Opportunities?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.